PRQR
ProQR Therapeutics N.V. NASDAQ Listed Sep 18, 2014$1.58
Mkt Cap $166.5M
52w Low $1.33
14.1% of range
52w High $3.10
50d MA $1.69
200d MA $2.00
P/E (TTM)
-4.1x
EV/EBITDA
-2.6x
P/B
3.3x
Debt/Equity
0.3x
ROE
—
P/FCF
-3.5x
RSI (14)
—
ATR (14)
—
Beta
0.09
50d MA
$1.69
200d MA
$2.00
Avg Volume
516.9K
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Zernikedreef 9 · Leiden, P7 2333 Ck · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | BMO | — | — | — | 1.58 | -0.6% | +0.0% | — | — | — | — | — |
| May 7, 2026 | BMO | — | — | — | 1.72 | +0.0% | -8.1% | — | — | — | — | — |
| Mar 12, 2026 | AMC | -0.08 | -0.09 | -12.5% | 1.72 | +0.6% | +5.8% | +2.3% | +2.9% | +0.0% | -7.6% | — |
| Nov 6, 2025 | AMC | -0.10 | -0.12 | -20.0% | 2.21 | -2.7% | +0.5% | -2.3% | -2.3% | -2.3% | -2.3% | — |
| Aug 7, 2025 | AMC | -0.08 | -0.14 | -75.0% | 2.05 | +2.0% | +5.9% | -7.8% | -6.8% | -1.5% | -1.5% | — |
| May 8, 2025 | AMC | -0.09 | -0.11 | -22.2% | 1.55 | -0.6% | +3.9% | +2.6% | -1.3% | +0.0% | +5.2% | — |
| Mar 13, 2025 | AMC | -0.10 | -0.10 | +0.0% | 1.74 | +2.3% | -2.9% | -2.3% | -5.7% | -6.3% | -6.3% | — |
| Nov 7, 2024 | AMC | -0.12 | -0.11 | +8.3% | 3.57 | +3.6% | +5.6% | +10.9% | +11.5% | +10.9% | +10.6% | — |
| Aug 8, 2024 | AMC | -0.12 | -0.03 | +75.0% | 2.06 | -2.9% | -2.9% | -2.9% | -2.4% | +8.7% | +8.3% | — |
| May 9, 2024 | AMC | -0.12 | -0.10 | +16.7% | 2.00 | +0.0% | -1.0% | -1.0% | -0.5% | -4.5% | -4.0% | — |
| Mar 13, 2024 | AMC | -0.08 | -0.08 | +0.0% | 2.33 | +0.9% | -0.4% | +9.9% | +6.0% | +7.7% | +6.0% | — |
| Nov 7, 2023 | AMC | -0.06 | -0.08 | -33.3% | 1.35 | +8.1% | +0.0% | +3.0% | +0.7% | +3.7% | +8.9% | — |
| Aug 3, 2023 | AMC | -0.12 | -0.11 | +8.3% | 1.43 | +0.7% | +5.6% | -0.7% | -4.9% | +4.2% | +7.0% | — |
| May 16, 2023 | AMC | -0.12 | -0.12 | +0.0% | 1.78 | +0.0% | -1.7% | -2.2% | +5.6% | +7.3% | +4.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Chardan Capital | Maintains | Buy → Buy | — | $1.83 | $1.88 | +2.7% | +8.2% | +1.1% | -1.6% | +8.7% | +8.7% |
| Nov 4 | Chardan Capital | Maintains | Buy → Buy | — | $2.59 | $2.50 | -3.5% | -8.1% | -8.1% | -14.7% | -14.3% | -16.6% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $2.05 | $2.09 | +2.0% | +5.9% | -7.8% | -6.8% | -1.5% | -1.5% |
| Jun 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.16 | $2.20 | +1.9% | -5.6% | -5.6% | -6.9% | -1.4% | +0.9% |
| Jun 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.16 | $2.20 | +1.9% | -5.6% | -5.6% | -6.9% | -1.4% | +0.9% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.59 | $1.60 | +0.6% | -3.8% | -2.5% | +2.5% | +1.9% | +7.5% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.78 | +2.3% | -2.9% | -2.3% | -5.7% | -6.3% | -6.3% |
| Mar 14 | Chardan Capital | Maintains | Buy → Buy | — | $1.74 | $1.78 | +2.3% | -2.9% | -2.3% | -5.7% | -6.3% | -6.3% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.38 | $3.40 | +0.6% | -2.7% | -16.3% | -26.9% | -13.0% | -24.0% |
| Dec 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.38 | $3.40 | +0.6% | -2.7% | -16.3% | -26.9% | -13.0% | -24.0% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $3.38 | $3.40 | +0.6% | -2.7% | -16.3% | -26.9% | -13.0% | -24.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.57 | $3.70 | +3.6% | +5.6% | +10.9% | +11.5% | +10.9% | +10.6% |
| Oct 29 | Raymond James | Upgrade | Outperform → Strong Buy | — | $3.31 | $3.70 | +11.8% | +4.2% | +10.6% | +5.7% | +12.7% | +9.7% |
| May 10 | Chardan Capital | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | -1.0% | -1.0% | -0.5% | -4.5% | -4.0% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | -1.0% | -1.0% | -0.5% | -4.5% | -4.0% |
| Apr 18 | Citigroup | Maintains | Neutral → Neutral | — | $1.90 | $1.94 | +2.1% | -2.1% | +4.7% | +5.3% | +6.3% | +5.8% |
| Mar 14 | Chardan Capital | Maintains | Buy → Buy | — | $2.33 | $2.35 | +0.9% | -0.4% | +9.9% | +6.0% | +7.7% | +6.0% |
| Mar 14 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.33 | $2.35 | +0.9% | -0.4% | +9.9% | +6.0% | +7.7% | +6.0% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.33 | $2.35 | +0.9% | -0.4% | +9.9% | +6.0% | +7.7% | +6.0% |
| Nov 8 | Chardan Capital | Upgrade | Neutral → Buy | — | $1.35 | $1.46 | +8.1% | +0.0% | +3.0% | +0.7% | +3.7% | +8.9% |
| Nov 8 | Raymond James | Maintains | Outperform → Outperform | — | $1.35 | $1.46 | +8.1% | +0.0% | +3.0% | +0.7% | +3.7% | +8.9% |
| Sep 18 | Citigroup | Maintains | Buy → Buy | — | $1.61 | $1.61 | +0.0% | -4.3% | -4.3% | -8.1% | -8.1% | -8.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | -6.0% | -9.9% | -1.3% | +1.3% | +1.3% |
| Aug 4 | Chardan Capital | Maintains | Neutral → Neutral | — | $1.43 | $1.44 | +0.7% | +5.6% | -0.7% | -4.9% | +4.2% | +7.0% |
| May 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.78 | $1.78 | +0.0% | -1.7% | -2.2% | +5.6% | +7.3% | +4.5% |
| May 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.78 | $1.78 | +0.0% | -1.7% | -2.2% | +5.6% | +7.3% | +4.5% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.78 | $1.78 | +0.0% | -1.7% | -2.2% | +5.6% | +7.3% | +4.5% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.56 | +1.6% | -21.0% | -15.5% | -10.7% | -13.1% | -11.9% |
| Dec 23 | Raymond James | Maintains | Outperform → Outperform | — | $2.70 | $2.57 | -4.8% | +0.4% | +19.3% | +13.3% | +24.8% | +37.0% |
| Dec 22 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $1.65 | $2.72 | +64.8% | +63.6% | +64.2% | +95.2% | +85.5% | +104.2% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.87 | +0.9% | +3.5% | +1.2% | -1.2% | -4.0% | -5.0% |
| Aug 12 | Chardan Capital | Downgrade | Buy → Neutral | — | $0.81 | $0.85 | +4.3% | +5.5% | +9.2% | +6.7% | +4.3% | +1.3% |
| Aug 12 | Raymond James | Upgrade | Market Perform → Outperform | — | $0.81 | $0.85 | +4.3% | +5.5% | +9.2% | +6.7% | +4.3% | +1.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.64 | $0.65 | +0.8% | -8.9% | -7.7% | -12.5% | -8.1% | -3.1% |
| May 6 | Chardan Capital | Maintains | Buy → Buy | — | $0.67 | $0.66 | -1.5% | -4.5% | -13.0% | -11.8% | -16.4% | -12.2% |
| Apr 14 | Chardan Capital | Maintains | Buy → Buy | — | $0.79 | $0.80 | +1.3% | -0.4% | -5.6% | -3.8% | -3.2% | -4.3% |
| Apr 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.79 | $0.80 | +1.3% | -0.4% | -5.6% | -3.8% | -3.2% | -4.3% |
| Feb 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.39 | $1.36 | -2.2% | -10.1% | -9.4% | -12.2% | -13.7% | -12.2% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.36 | -2.2% | -10.1% | -9.4% | -12.2% | -13.7% | -12.2% |
| Feb 14 | Chardan Capital | Maintains | Buy → Buy | — | $1.39 | $1.36 | -2.2% | -10.1% | -9.4% | -12.2% | -13.7% | -12.2% |
| Feb 14 | Raymond James | Downgrade | Strong Buy → Market Perform | — | $1.39 | $1.36 | -2.2% | -10.1% | -9.4% | -12.2% | -13.7% | -12.2% |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | $6.26 | $6.32 | +1.0% | +0.2% | -0.2% | +0.6% | +5.6% | +0.5% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $5.45 | $5.50 | +0.9% | +4.0% | -2.4% | -3.7% | -3.3% | -5.3% |
| Nov 19 | Citi | Maintains | Buy → Buy | — | $6.25 | $6.27 | +0.3% | +6.6% | +23.0% | +30.9% | +34.4% | +32.0% |
| Nov 19 | Citigroup | Maintains | Buy → Buy | — | $6.25 | $6.27 | +0.3% | +6.6% | +23.0% | +30.9% | +34.4% | +32.0% |
| Sep 26 | Leerink Swann | Maintains | Outperform → Outperform | — | $6.45 | $6.05 | -6.2% | -19.4% | -20.2% | -24.8% | -24.8% | -25.6% |
| Mar 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.69 | $4.89 | +4.3% | -0.2% | -6.6% | -12.4% | -9.0% | -7.2% |
No insider trades available.
Data updated apr 26, 2026 8:50pm
· Source: massive.com